TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
31.8.2021 09:00:00 EEST | Business Wire | Press release
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers while existing shareholders were led by Sofinnova Partners, a historical cornerstone investor, reinforcing TISSIUM shareholding structure. As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining TISSIUM’s board of directors.
This latest funding round coincides with a period of rapid growth at TISSIUM that is expected to continue as it scales its operations and adds to its executive team. The financing will allow TISSIUM to continue to execute on its development plan, funding the company up to the commercialization of its leading nerve repair, hernia repair and cardiovascular sealant products.
As TISSIUM adds to its platform with products in new therapeutic areas, it will continue to pursue rapid international expansion, leveraging in-house production and state-of-the-art manufacturing facilities, as well as entering partnerships in certain verticals.
Christophe Bancel, CEO of TISSIUM, said, “With the closing of our Series C financing round, TISSIUM is well-positioned to take the next steps to commercialization. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. This financing will contribute significantly to TISSIUM’s ability to take advantage of the variety of opportunities we have to advance our innovation in this space.”
Antoine Papiernik, Managing Partner at Sofinnova Partners, said, “At Sofinnova Partners, we have been convinced since the beginning of TISSIUM’s potential to revolutionize tissue repair and bring a truly innovative solution for patients worldwide. We are pleased to be joined by Cathay Health and other investors who share this vision as we continue to support TISSIUM and provide the means for this exceptional team to pursue its development and prepare the commercialization of its lead products.”
Hongjie Hu, Co-founder and Managing Partner of Cathay Health, said, “TISSIUM is creating the future of tissue reconstruction on all continents. Its expandable platform is solving for widespread problems in surgeries addressing the needs of atraumatic repairs and can be applied to multiple, large, unmet therapeutic areas. As a cross-border investment platform spanning the US, Europe and Asia, we look forward to bringing the global outlook, resources and health ecosystem to support TISSIUM’s brilliant team in its international expansion and for the next steps toward commercialization and growth.”
About TISSIUM:
TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
For more information, please visit: www.TISSIUM.com
Follow us on LinkedIn, Twitter @TISSIUMtech.
About Cathay Health and Cathay Capital Group:
Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. Affiliated to Cathay Capital, Cathay Health is a global cross-border platform investing at the convergence of healthcare, life sciences and technology. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages over $4,2B in assets, has completed over 180 buyouts, growth and venture capital investments with global reach and local expertise across Paris, London, Munich, New York, Boston, San Francisco, Shanghai, Beijing, Singapore and Shenzhen.
For more information, please visit www.cathaycapital.com
Follow us on LinkedIn, Twitter @CathayCapital
About Sofinnova Partners:
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005572/en/
Contact information
Investor relations
Romain Attard – Chief Financial Officer
Tel: +33 1 76 21 72 28
rattard@tissium.com
Twitter: @TISSIUMtech
Press
Jeanene Timberlake
Tel: +1 646-770-8858
jtimberlake@rooneypartners.com
Yoann Besse
Tel: +33 6 63 03 84 91
yoann.besse@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenNx360 Capital Partners Promotes Pratik Rajeevan to Partner17.6.2026 14:00:00 EEST | Press release
GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, is thrilled to announce the promotion of Pratik Rajeevan to Partner. Pratik has significant transaction experience having invested in over ten platform companies and 30 add-on investments during his tenure at GenNx360. His experience includes investments in aerospace and defense, utility and environmental services, and testing and inspection services. Pratik is a key leader in investments in NVI, Shenandoah, and Aeron in the GenNx360 Fund IV portfolio. Pratik led successful investments and exits in Miller Environmental and Aero3 in GenNx360 Fund III. Most recently, Pratik was responsible for the firm’s $2 billion exit from Precision Aviation Group, a global aerospace and defense maintenance and repair business in GenNx360 Fund IV. “Pratik is a disciplined and thoughtful investor with significant execution capabiliti
Vercel Brings New Agent Framework, Full-Stack Capabilities, and Enterprise Controls to Its Agentic Infrastructure Platform17.6.2026 13:13:00 EEST | Press release
Today at Ship, its annual conference, Vercel introduced a set of new products that deepen its agentic infrastructure platform trusted by DoorDash, Helly Hansen, OpenAI, Stripe, and The Weather Company. Founder and CEO Guillermo Rauch and other Vercel leaders unveiled the lineup on stage, anchored by three shifts the products address: agents are now the dominant way software gets deployed, every application is becoming agentic, and enterprises need to run agents in production securely and at scale. The transition is well underway. Six months ago, fewer than three percent of deployments to Vercel infrastructure were triggered by coding agents. Agents now account for more than half. Token volume through Vercel's AI Gateway has grown from roughly two trillion to twenty trillion per month over the same period. And over the past year, Vercel has invested heavily in Python and backend frameworks, with a growing share of customers now running backends and databases alongside their frontends. "
NIQ Introduces NIQ Cadence: A Compound AI Operating System for Marketing Effectiveness17.6.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today introduced NIQ Cadence, a compound AI operating system built to change how organizations measure marketing performance, optimize budgets, and act on what the data tells them. NIQ Cadence brings data and intelligence into one continuous environment, moving marketers off fragmented reports and onto a single system that empowers decision making. Marketing has never been more complex. Channels keep multiplying, data sits in silos, and the pressure to prove ROI keeps climbing. As a result, most teams still stitch insight and action together by hand, losing time and confidence at every handoff. NIQ Cadence closes that gap with one system where measurement and decision-making finally run together. “Marketing leaders don’t need more reports. They need a better rhythm,” said Jason Tate, General Manager of Marketing Effectiveness at NIQ. “NIQ Cadence moves organizations beyond disconnected data, siloed tools, and disparate insights
WISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New Investor17.6.2026 13:00:00 EEST | Press release
WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), today announced the successful closing of an oversubscribed Series D financing round totaling €30 million. The round was joined by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector, which enters WISE's investor base as a strategic partner. This final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank (EIB) supported by InvestEU, alongside an equity investment from new investor Wallaby S.p.A. — the family office of the Scagliarini family (GVS S.p.A.) — and existing financial partners New Frontier S.r.l., Eureka Venture SGR, and Indaco Ventures SGR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20
Winning With AI Requires Organizational Transformation, Not Speed of Adoption, Finds New Arthur D. Little Report17.6.2026 13:00:00 EEST | Press release
To successfully embrace the power of AI, businesses need to remove organizational complexity and eliminate unnecessary work, rather than simply using it for fragmented, incremental improvements. Boards must act now to deliver this. That is the key message from AI-First or Disrupted: Beating the Nightmare Competitor, a new report from Arthur D. Little (ADL) based on concrete examples from leading organizations. Within three to five years, AI-first competitors will make faster decisions, have flatter organizations, and operate at lower costs. They will not just optimize handovers between teams, approvals, and reconciliation work; they will eliminate these complex processes entirely. AI is completely changing the economics of work and value creation, removing the need for coordination across multiple teams, while also enabling adaptive, predictive, and personalized products and services. This delivers both lower operational costs and a fundamentally stronger value proposition. However, mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom